Overview A Study of JR-141 in Patients With Mucopolysaccharidosis II Status: Completed Trial end date: 2020-02-20 Target enrollment: Participant gender: Summary A Phase II/ III multicenter, open-label, single-group, designed to evaluate the efficacy and safety of study drug for the treatment of the MPS II. Phase: Phase 2/Phase 3 Details Lead Sponsor: JCR Pharmaceuticals Co., Ltd.